Background {#Sec1}
==========

In oral surgery, the operation of the impacted third molar is one of the most common surgical procedures performed by oral and maxillofacial surgeons \[[@CR1]\]. After the impacted third molars are removed in the early postoperative stage, patients usually present complications such as pain, swelling, and trismus \[[@CR2], [@CR3]\]. These inflammatory complications are crucial for patients and surgeons in order to develop the customized strategy for reducing the risk of complications and improving postoperative healing \[[@CR4]\]. Several attempts using platelet-rich plasma administration, preoperative and postoperative antibiotics, cryotherapy, wound draining, the use of different kinds of flaps, and osteotomy using high- or low-speed rotary instruments, postoperative ice packs, analgesics, corticosteroids, and laser have been made to reduce the postoperative outcome of the removal of the third molar post-surgery \[[@CR5]--[@CR9]\].

Platelet-rich fibrin (PRF) is a novel strategy for concentrating the platelets (the preparation process without thrombin), which can be used for the enhancement after tooth extraction and residual cyst bone formation and promotion of the wound epithelialization \[[@CR10]--[@CR14]\]. The PRF originates from the slow, gradual polymerization occurring during centrifugation \[[@CR15]\]. This is the second generation of immune platelet concentrate, collected as single fiber membrane protein components of the blood sample. These components are utilized for healing and immune regulation, especially, fibrin matrix in which, growth factors (vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-A1, platelet-derived growth factor (PDGF)-AA, and insulin-like growth factor 1, leukocytic cells, and their cytokines such as, interleukin (IL)-4, IL-6, IL-1A, and tumor necrosis factor (TNF)) are enmeshed \[[@CR10]--[@CR14]\].

PRF is widely used for mandibular third molar surgery; however, its effect on potential post-surgical complications is unclear. The efficiency of local application of PRF to control the postoperative complications after the extraction of an impacted lower third molar has been investigated by several meta-analyses. Two previous meta-analyses conducted by Al-Hamed et al. \[[@CR16]\] and Canellas et al. \[[@CR17]\] had limitations since only two randomized controlled trials (RCTs) were included in the quantitative synthesis that compared the relevant interventions. Recently, He et al. \[[@CR18]\] conducted a systematic review and meta-analysis to evaluate the efficacy of PRF on a mandibular third molar. These meta-analyses were followed by several RCTs on the same topic; however, the findings were controversial and no updated meta-analysis is yet available. Herein, we identified the eligible studies \[[@CR19]--[@CR21]\] and performed a detailed analysis at different time points. The present systematic review and meta-analysis investigated and assessed whether PRF was effective and safe for patients during the extraction of bilateral mandibular third molars.

Methods {#Sec2}
=======

This study was designed in compliance with the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement \[[@CR22]\].

Search strategy {#Sec3}
---------------

The potentially relevant studies were identified by searching Pubmed, Embase, and the Cochrane library. A systematic and comprehensive search was performed on the three databases using a combination of keywords and medical subheadings: "platelet-rich fibrin" or "PRF", "oral surgery", and "third molar"(Additional file [1](#MOESM1){ref-type="media"}: Table S1). Alternative spellings and abbreviations were also considered. To identify additional studies, the reference lists of the included studies and relevant reviews were also searched manually. The literature search was limited to the English language, and the last search was performed on September 3, 2017 by two authors, independently, using a standardized approach. Any inconsistencies between the two authors were settled by group discussion to achieve a consensus.

Selection criteria {#Sec4}
------------------

The inclusion criteria included: 1) patients with bilateral mandibular third molars required surgical extraction; 2) at least two comparison groups: one group received PRF at the mandibular third molar and the other group received control treatment without PRF; 3) published in the English literature; 4) outcomes: alveolar osteitis, osteoblastic activity, pain, swelling, trismus, and soft tissue healing. The exclusion criteria were as follows: 1) the inclusion criteria were not fulfilled; 2) studies on the same population or overlapping database.

Data extraction and quality assessment {#Sec5}
--------------------------------------

The available data were extracted from each study by two investigators, independently, according to the inclusion criteria listed above; any disagreement was subsequently resolved by discussion with a third author. The following data were collected from each study: first author's name, publication year, a country where the research was performed, number of patients, the gender of patients, mean age of the patients, time of follow-up, study design, and the outcomes. The quality of the RCTs was evaluated using the Cochrane Collaboration's tool for assessing the risk of bias \[[@CR23]\]. The assessment included the following components: random sequence generation, allocation concealment, blinding of patients, study personnel, blinding of outcome assessment, completeness of the outcome data, selective reporting of outcomes, and the other threats to validity (i.e. intention-to-treat analysis and completeness of follow-up). All these domains can be rated as either high, low, or unclear. Quality of evidence was assessed across important outcomes using GRADE approach to support management recommendations by the GRADEpro software (version 3.6). The criteria were based on study design, limitations, inconsistency, indirectness, imprecision, and other considerations. The quality of evidence was rated as high, moderate, low, or very low.

Statistical analysis {#Sec6}
--------------------

We calculated the weighted mean difference (WMD) (continuous variables with same unit)/standard mean difference (SMD) (continuous variables with different unit) and 95% confidence intervals (CIs) for the continuous data, and the risk ratio (RR) and 95% CIs were calculated for dichotomous data. The heterogeneity of the studies was assessed using the Cochran's Q test \[[@CR24]\] that was quantified by the *I*^*2*^ statistic (considered as high heterogeneity for *I*^*2*^ \> 50%). Preliminary analysis was conducted using a fixed-effects model (Mantel--Haenszel method) \[[@CR25]\]; in the case of high heterogeneity, a random effects model was employed (Der Simonian and Laird) \[[@CR26]\]. The relative influence of each study on the pooled estimate was assessed by excluding each study sequentially for sensitivity analysis. The publication bias was evaluated by visual inspection of the symmetry of the funnel plot and assessment of Begg's and Egger's test (*P* \< 0.05 is representative of statistical significance) \[[@CR27]\]. Statistical analyses were conducted using STATA software, version 12.0 (STATA Co., College Station, TX, USA), and all tests were two-sided.

Results {#Sec7}
=======

Characteristics of the studies {#Sec8}
------------------------------

A total of 98 articles were identified from the databases and manual search as described above. After excluding the duplicates, 69 articles were remaining. Subsequently, we evaluated the remaining articles and 42 were discarded because of irrelevance. Of the remaining 27 articles, 9 were excluded as they were letters, reviews, and meta-analysis. The remaining 18 full-text articles were assessed for potential eligibility, of which, 4 were excluded for comparing the PRF with other interventions, 3 were without usable data, and 1 was a case-control study. Finally, a total of 10 studies \[[@CR19]--[@CR21], [@CR28]--[@CR34]\] fulfilled the inclusion and exclusion criteria in this systematic review and meta-analysis (Fig. [1](#Fig1){ref-type="fig"}). The main characteristics of the eligible studies are summarized in Table [1](#Tab1){ref-type="table"}. These 10 studies were also assessed qualitatively using the tools recommended by the Cochrane Collaboration for the risk of bias. A graph and summary of selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases identified in each study are shown in Fig. [2](#Fig2){ref-type="fig"}a and b. A previous study \[[@CR34]\] had a high risk of bias in allocation concealment, 3 studies \[[@CR20], [@CR21], [@CR31]\] had a high risk of bias in blinding of participants and personnel, and 3 studies \[[@CR20], [@CR21], [@CR28]\] had a high risk of bias in blinding of outcome assessment. The quality of the evidence of each result was shown in Table [2](#Tab2){ref-type="table"}. The evidence was graded as 'moderate quality' for swelling, 'low quality' for pain, alveolar osteitis, and soft tissue healing, and 'very low quality' for trismus and osteoblastic activity. The quality of evidence was downgraded to 'moderate', 'low' or 'very low' mainly due to high risk of performance bias (randomization and blinding), inconsistency (significant heterogeneity) and imprecision (pooled results included no effects).Fig. 1Schematic representation of the identification of the studiesTable 1Characteristics of the studies included in this meta-analysisAuthor/year of publicationCountryGenderMean age (Y)InterventionFollow-up (d)Study designOutcomes assessedPRFControlGürbüzer/2010 \[[@CR28]\]Turkey7 males and 7 females24.92 ± 4.69Y141428dRCT, split-mouthOsteoblastic activityEshghpour/2014 \[[@CR29]\]Iran33 males and 45 females25.09 ± 4.25Y78782 and 7dRCT, split-mouthAlveolar osteitisBaslarli/2015 \[[@CR30]\]Turkey7 males and 13 females23.9Y202030 and 90dRCT, split-mouthAlveolar osteitis, osteoblastic activityKumar/2015 \[[@CR31]\]IndiaNAPRF:25.25 ± 4.2Y Control:27 ± 5.27Y161590dRCTTrismusOzgul/2015\[[@CR32]\]Turkey23 males and 33 femalesNA56561,3, and 7dRCT, split-mouthPain, swellingUyanık/2015 \[[@CR33]\]Cyprus4 males, 6 females22.65Y10101,2,3, and 7dRCT, split-mouthPain, swelling, trismusBilginaylar/2016 \[[@CR34]\]Cyprus22 males and 37 femalesPRF:21.75Y Control:22.5Y40401,2,3, and 7dRCTPain, swelling, trismusDutta/2016 \[[@CR19]\]India27 males and 13 females27 ± 5Y10103,7, and 14dRCTPain, swelling, soft tissue healingAl-Hamed/2017 \[[@CR16]\]Egypt13 males and 34 females25.24 ± 7.04Y25252,3,4,5,6, and 7dRCTPain, alveolar osteitis, soft tissue healingGülşen/2017 \[[@CR21]\]Turkey21 males and 9 females20.03Y30301,2,3, and 7dRCT, split-mouthPain*Y* years, *d* days, *RCT* randomized controlled trial, *NA* Not availableFig. 2Risk of bias assessment for the randomized trials included in the meta-analysis. **a** Risk of bias summary; **b** Risk of bias graph. *Symbols*. (+): low risk of bias; (?): unclear risk of bias; (−): high risk of biasTable 2Summary of findings tableImpact of PRF on mandibular third molar surgery recoveryPatient or population: patients with mandibular third molar surgery recovery\
Settings: outpatient\
Intervention: PRF\
Comparison: Non-PRFOutcomesIllustrative comparative risks\* (95% CI)Relative effect\
(95% CI)No of Participants\
(studies)Quality of the evidence\
(GRADE)CommentsAssumed riskCorresponding riskNon-PRFPRFPainVisual analog scaleFollow-up: 1-7 daysThe mean pain in the control groups was 7.52The mean pain in the intervention groups was 0.53 standard deviations lower(1.02 to 0.05 lower)322(6 studies)⊕⊕⊝⊝low^1,2^SwellingA flexible rulerFollow-up: 1-7 daysThe mean swelling in the control groups was 20.79The mean swelling in the intervention groups was 0.55 standard deviations lower(1.08 to 0.01 lower)212(4 studies)⊕⊕⊕⊝moderate^3^TrismusMeasuring the distanceFollow-up: 1-7 daysThe mean trismus in the control groups was 24.35The mean trismus in the intervention groups was 0.09 standard deviations lower(0.68 lower to 0.5 higher)131(4 studies)⊕⊝⊝⊝very low^3,4,5^Alveolar osteitisFollow-up: 2-90 days179 per 100063 per 1000(29 to 134)RR 0.35(0.16 to 0.75)246(3 studies)⊕⊕⊝⊝low^1,5^Osteoblastic activityFollow-up: 28-90 daysThe mean osteoblastic activity in the control groups was 4.29The mean osteoblastic activity in the intervention groups was 0.05 higher(0.44 lower to 0.55 higher)68(2 studies)⊕⊝⊝⊝very low^1,2,5^Soft tissue healingFollow-up: 2-14 daysThe mean soft tissue healing in the intervention groups was 1.03 higher(0.32 lower to 2.38 higher)70(2 studies)⊕⊕⊝⊝low^1,4^\*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)*CI* Confidence interval, *RR* Risk ratio;GRADE Working Group grades of evidenceHigh quality: Further research is very unlikely to change our confidence in the estimate of effectModerate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimateLow quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimateVery low quality: We are very uncertain about the estimate^1^ Having non-blinded study^2^ The significant heterogeneity^3^ No allocation concealment^4^ Risk of bias^5^ Pooled results included no effects

Quantitative synthesis {#Sec9}
----------------------

*Postoperative pain*: The 6 studies \[[@CR19]--[@CR21], [@CR32]--[@CR34]\] that provided the outcomes regarding the postoperative pain in patients, who received PRF and control treatments, were included in the meta-analysis. A significant difference was observed in the postoperative pain on the third day (SMD = − 0.53, 95% CI: − 1.02 to − 0.05, *P*~heterogeneity~ = 0.001, *I*^*2*^ = 75.7%) between the two groups (Fig. [3](#Fig3){ref-type="fig"}a); however, no significant difference was noted on the first day (SMD = − 0.38, 95% CI: − 1.01--0.24, *P*~heterogeneity~ = 0.001, *I*^*2*^ = 82.1%) and seventh day (SMD = − 1.05, 95% CI: − 2.14--0.03, *P*~heterogeneity~ \< 0.001, *I*^*2*^ = 90.3%). To explore the possible sources of heterogeneity, we conducted subgroup analyses according to measuring method. The results are summarized in Table [3](#Tab3){ref-type="table"}. Furthermore, the between-study heterogeneity within subgroups remained substantial in most analyses.Fig. 3Forest plots showing the effect of PRF vs. control after mandibular third molar surgery. **a** Pain; **b** Swelling; **c** Trismus; **d** Alveolar osteitis; **e** Osteoblastic activity; **f** Soft tissue healingTable 3Subgroup analysis of the meta-analysisOutcomesSubgroupNumber of trialsEffect (95% CI)Estimate for overall effectHeterogeneityPainTotal(1 day)4−0.38(−1.01,0.24)*P* = 0.231*I*^2^ = 82.1%, *P* = 0.001VAS(1 day)3−0.59 (−1.45, 0.27)*P* = 0.181*I*^2^ = 86.1%, *P* = 0.001VAS and VRS(1 day)10.16 (− 0.35, 0.66)*P* = 0.545Total(3 day)6−0.53(−1.02,0.05)*P* = 0.032*I*^2^ = 75.7%, *P* = 0.001VAS(3 day)5−0.67 (−1.26, − 0.08)*P* = 0.026*I*^2^ = 78.6%, *P* = 0.001VAS and VRS (3 day)1−0.01 (− 0.51, 0.50)*P* = 0.975Total(7 day)4−1.05 (−2.14, 0.03)*P* = 0.057*I*^2^ = 90.3%, *P* \< 0.001VAS(7 day)3− 1.62 (−3.63, 0.39)*P* = 0.113*I*^2^ = 93.2%, *P* \< 0.001VAS and VRS (7 day)10.07 (− 0.44, 0.58)*P* = 0.786TrismusTotal4−0.19 (− 0.88, 0.50)*P* = 0.596*I*^2^ = 73.1%, *P* = 0.011Ustun method3−0.46 (− 0.99, 0.07)*P* = 0.088*I*^2^ = 39.7%, *P* = 0.190Other10.77 (0.04, 1.50)*P* = 0.039*VAS* visual analogue scale, *VRS* verbal scale

Postoperative swelling {#Sec10}
----------------------

The 4 studies \[[@CR19], [@CR32]--[@CR34]\] that provided outcomes regarding the postoperative swelling in patients, who received PRF and control treatments, were included in the meta-analysis. A significant difference was observed in the postoperative swelling on the first day (WMD = − 0.55, 95% CI: − 1.08 to − 0.01, *P*~heterogeneity~ = 0.573, *I*^*2*^ = 0) between the two groups (Fig. [3](#Fig3){ref-type="fig"}b); however, no significant difference was observed on the third day (WMD = − 1.00, 95% CI: − 2.17--0.17, *P*~heterogeneity~ \< 0.001, *I*^*2*^ = 94.8%) and seventh day (WMD = − 0.61, 95% CI: − 1.32--0.10, *P*~heterogeneity~ = 0.046, *I*^*2*^ = 74.9%).

Trismus {#Sec11}
-------

This outcome was reported in 3 trials \[[@CR31], [@CR33], [@CR34]\] that compared PRF to the control treatments. Any significant difference was not observed in the trismus on the first day (SMD = − 0.19, 95% CI: − 0.88--0.50, *P*~heterogeneity~ = 0.011, *I*^*2*^ = 73.1%) (Fig. [3](#Fig3){ref-type="fig"}c), third day (SMD = − 0.25, 95% CI: − 0.64--0.15, *P*~heterogeneity~ = 0.491, *I*^*2*^ = 0), and seventh day (SMD = − 0.25, 95% CI: − 0.64--0.15, *P*~heterogeneity~ = 0.764, *I*^*2*^ = 0) between the two groups. To explore the possible sources of heterogeneity, we conducted subgroup analyses according to measuring method. The results are summarized in Table [3](#Tab3){ref-type="table"}. Furthermore, the between-study heterogeneity within subgroups was significantly reduced.

Alveolar osteitis {#Sec12}
-----------------

The outcome was reported in 3 trials \[[@CR20], [@CR29], [@CR30]\], and a fixed effects model did not reveal any significant heterogeneity between the studies. However, a significant difference was observed in the incidence of alveolar osteitis (RR = 0.35, 95% CI: 0.16--0.75, *P*~heterogeneity~ = 0.597, *I*^*2*^ = 0%) between the two groups (Fig. [3](#Fig3){ref-type="fig"}d).

Osteoblastic activity {#Sec13}
---------------------

This outcome was reported in 2 trials \[[@CR28], [@CR30]\] that compared PRF to the control treatments. No significant heterogeneity was found between the studies as assessed by the fixed effects model. Also, no significant difference was observed in the osteoblastic activity (WMD = 0.05, 95% CI: − 0.44--0.55, *P*~heterogeneity~ = 0.681, *I*^*2*^ = 0%) between the two groups (Fig. [3](#Fig3){ref-type="fig"}e).

Soft tissue healing {#Sec14}
-------------------

This outcome was reported in 2 trials \[[@CR19], [@CR20]\]. A significant heterogeneity occurred between the two studies as evaluated by the random effects model. However, no significant difference was observed in the soft tissue healing (WMD = 1.03, 95% CI: − 0.32--2.38, *P*~heterogeneity~ \< 0.001, *I*^*2*^ = 96.7%) between the two groups (Fig. [3](#Fig3){ref-type="fig"}f).

Sensitivity analysis {#Sec15}
--------------------

Sensitivity analyses were performed to assess the influence of individual dataset on the pooled estimate by sequential removal of each eligible study. However, the overall statistical significance did not change, indicating the robustness of the current results (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Sensitivity analysis of the effect of PRF vs. control after mandibular third molar surgery. **a** Pain; **b** Swelling; **c** Trismus

Publication bias {#Sec16}
----------------

Finally, the Egger's regression test did not show any significant evidence of asymmetrical distribution in the funnel plot in trismus (Begg's test *P* = 0.734; Egger's test *P* = 0.677) and alveolar osteitis (Begg's test *P* = 1.000; Egger's test *P* = 0.198) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Funnel plot for publication bias test. Each point represented an independent study for the indicated association. **a** Trismus; **b** Alveolar osteitis

Discussion {#Sec17}
==========

The physiological additives modulate the inflammation and increase the therapeutic effect postoperatively; the use of fibrin adhesives has been documented in the past three decades \[[@CR12]--[@CR14]\]. However, due to the risk of cross-infection and cumbersome protocols for preparation, the use of these additives has been controversial. The present systematic review and meta-analysis was conducted to assess the effect of PRF on the healing process of the alveolar socket after surgical extraction of the mandibular third molars. The current results showed a beneficial effect of PRF in relieving pain and swelling and reducing the incidence of alveolar osteitis after the extraction of an impacted lower third molar. However, no statistically significant difference was observed between the two groups with respect to trismus, osteoblastic activity, and soft tissue healing. PRF is the second generation of platelet concentrates (PRP is the first generation). It is characterized by slow polymerization during preparation, which produces a fibrous protein network similar to the natural cells in order to enhance cell migration and proliferation. As a reservoir of platelets, cytokines, leukocytes, and immune cells, PRF allows a sustained release of cytokines such as VEGF, PDGF, TGF, and epidermal growth factor (EGF) that play a key role in vascular and tissue healing and scarring \[[@CR11], [@CR13], [@CR14]\]. Reportedly, PRF also enhances angiogenesis, supports immunity, and increases the coverage of the injured tissue by enhancing the positive effects on epithelial cells and fibroblasts \[[@CR11]\]. In oral and maxillofacial regions, PRF is widely used in simple graft or combination with allograft or xenograft \[[@CR35]\]. In addition, the PRF clots are used for the flapless treatment of acute sinus perforations \[[@CR36]\]. The extraction for socket preservation, intrabony defects, and periodontal problems are the other indications of PRF usage \[[@CR11]\].

To the best of our knowledge, the current meta-analysis is the largest study investigating the impact of PRF on a mandibular third molar in 314 patients from 10 studies. Compared to the studies by Al-Hamed et al. \[[@CR16]\] and Canellas et al. \[[@CR17]\], we found that the local application of PRF, during the extraction of the lower third molar, significantly relieved pain on the postoperative third day and swelling on the postoperative first day by meta-analysis, while the previous studies did not perform a quantitative data synthesis because of the limited available data. Compared to the study by He et al. \[[@CR18]\], we found that the local application of PRF, during the extraction of the lower third molar, significantly relieved the swelling on the postoperative first day, while the previous study indicated that PRF significantly relieved the postoperative swelling on the third day. This inconsistency in the result might be attributed to the newly identified eligible study. Heterogeneity is a potential issue when interpreting the results of meta-analyses, in which, heterogeneity was detected while analyzing the pain and soft tissue healing; thus, the random-effects model was used. Different study types, scales of measurement, time intervals, and surgical protocols are possible explanations for the heterogeneity. Furthermore, sensitivity analyses were also conducted by sequential exclusion of each eligible study. However, the pooled estimate did not alter significantly, thereby strengthening the conclusions.

Furthermore, the current meta-analysis also presented some limitations: First, the number of studies for some parameter analysis was small, which might lessen the statistical power. Second, the studies exhibited significant heterogeneity. Different study types, scales of measurement, time intervals, and surgical protocols are possible explanations for the heterogeneity. Third, bias could be introduced if studies published in a language other than English were excluded. Finally, the follow-up time varied considerably among the 10 studies, which ranged from 1 to 90 days and limited the assessment of long-term clinical effects of PRF on the mandibular third molar.

Conclusions {#Sec18}
===========

In conclusion, despite the limitations of the meta-analysis, our study confirmed that PRF only reduces some of the postoperative complications but does not prevent them. PRF administered after third molar extraction significantly relieved pain, swelling, and reduced the incidence of alveolar osteitis. Therefore, further studies with a larger dataset and well-designed models are essential to validate the current findings.

Additional file
===============

 {#Sec19}
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:   Epidermal growth factor
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:   Randomized controlled trials
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WMD
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